Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Drug development

Topic: Brain proteins, microglia and lab models

Plain-language summary

Neurodegenerative disorders (NDDs), primarily alzheimer, dementia, parkinson, and rare NDD disease, present an escalating global health crisis, currently affecting over 55 million older adults worldwide. Current therapeutic options are largely limited to temporary symptomatic relief, fundamentally failing to modify underlying disease progression. Consequently, drug repurposing has emerged as a crucial strategy, with Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs) such as exenatide, liraglutide, semaglutide; gaining significant attention. Despite the growing body of RWE evaluating the real-world safety and effectiveness of these drugs in NDDs, there is a distinct lack of comprehensive scoping reviews to encapsulate, categorize, and synthesize these scattered observational findings. To address this gap, we are conducting a scoping review to systematically map the available real-world evidence of GLP-1 RAs for neurodegenerative disorders, outlining current clinical insights and directing future trial designs.

What this study adds

Evidence grade: Low

This is a plan for a scoping review that will map existing observational studies of GLP-1 receptor agonists in neurodegenerative disorders. It reports no new results and therefore cannot say whether these drugs treat or prevent Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Sharma, S., Veeranki, P., Mubayi, D. A., & Nambari, S. (2026). Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies. Open Science Framework. https://doi.org/10.17605/osf.io/ng7mu

Vancouver

Sharma S, Veeranki P, Mubayi DA, Nambari S. Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies. Open Science Framework. 2026. doi:10.17605/osf.io/ng7mu.

BibTeX

@article{sharma2026-0b097590,
  author  = {Sharma, Shubham and Veeranki, Phani and Mubayi, Dr Anuj and Nambari, Santosh},
  title   = {{Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies}},
  journal = {Open Science Framework},
  year    = {2026},
  doi     = {10.17605/osf.io/ng7mu},
  url     = {https://doi.org/10.17605/osf.io/ng7mu}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This is a plan for a scoping review that will map existing observational studies of GLP-1 receptor agonists in neurodegenerative disorders. It reports no new results and therefore cannot say whether these drugs treat or prevent Alzheimer's disease.

Study details

How this study scored 31/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 26 of the 83 points it could be judged on, which is 31 of 100. Total 31 of 100.26 of the 83 points we could judge = 31 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, impact for its field and year, senior author's track record and institution's track record, so those were left out: it earned 26 of the 83 points we could judge it on, which is 31 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Open Science Framework)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Santosh Nambari holds only 1 work(s), too few to judge a track record — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 26 / 83 Scored on 16 of 20 parts. We have no data for the rest, so they are left out: 26 of the 83 points we could judge it on is 31 out of 100.
Total 31 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Drug development from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Drug development

See all studies in Drug development →